Inflammatory tumor response to monoclonal antibody infusion.
Two patients with melanoma and one with apudoma, all three with metastatic disease, received monoclonal antibody infusions with mAb R-24, specific for the disialoganglioside GD3. This marker was shown to be restricted to melanoma cells and a few other tumors of neural crest origin. Following treatment with mAb R-24 both melanoma patients showed inflammatory cutaneous responses around tumor nodules, i.e. blister formation or inflammatory perinodular halos. Local pain in bulky intestinal tumor sites occurred in all three patients about 3 hr after onset of antibody infusion. Adverse side-effects of antibody application were not observed with antibody doses up to 200 mg (single) and 440 mg total dose. The presented data indicate that mAb R-24 is active in vivo.
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001079:Apudoma / Q000276:immunology / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D003872:Dermatitis / Q000473:pathology; D005732:Gangliosides / Q000276:immunology; D006801:Humans; D007249:Inflammation / Q000209:etiology*; D008297:Male; D008545:Melanoma / Q000276:immunology / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D010865:Pilot Projects; D012867:Skin / Q000473:pathology
D000911:Antibodies, Monoclonal; D005732:Gangliosides; C026226:ganglioside, GD3